(Updates)
** U.S.-listed shares of Australia's Immuron Ltd IMRN.O
rise 28.3% to $2.4
** Co's stock surged 72.7% in premarket trading
** Co IMC.AX says FDA removes clinical hold, allowing the
U.S. Naval Medical Research Center to evaluate efficacy of
diarrhoea drug, Travelan
** Travelan, co-developed with Immuron, is an oral
immunotherapeutic drug to treat gut-mediated diseases caused by
various types of bacteria
** Drug's safety and efficacy will be tested in two trials,
with one focusing on the drug's ability against ETEC infections
and the focusing on moderate to severe campylobacteriosis
** Including session's gain, stock up 15.4% YTD
(Reporting by Sriparna Roy and Pratik Jain in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))